



Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

Endari® Granted Orphan Drug Status in Switzerland

Dec 3 2020, 11:20 AM EST

Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®

Nov 10 2020, 11:25 AM EST

FDA Approves Updated Label for Endari®

Nov 3 2020, 11:30 AM EST

Stock Overview

Symbol	EMMA
Exchange	OTCQB
Market Cap	51.62m
Last Price	\$1.06
52-Week Range	\$0.70 - \$2.80

12/04/2020 01:54 PM EST

Management Team

Yutaka Niihara, MD, MPH

Chief Executive Officer, Chairman of the Board

Willis C. Lee

Chief Operating Officer, Vice-Chairman of the Board

Yasushi Nagasaki, CPA

Senior Vice President of Finance, Interim Chief Financial Officer

George Sekulich

Senior Vice President of Global Commercialization and Chief Information Officer

Dale E. Short

General Counsel

Charles W. Stark, PharmD

Senior Vice President of Research and Development

Lan T. Tran

Chief Administrative Officer

Emmaus Life Sciences, Inc.

21250 Hawthorne Blvd.
Suite 800
Torrance, CA 90503

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.